Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 138

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 138
---
 404 of the Sarbanes-Oxley Act
and were therefore not required to make a formal assessment of the effectiveness of control over financial reporting for that purpose.
As a public company, we will be required to provide an annual management report on the effectiveness of our internal control over financial
reporting commencing with our annual report on Form 10-K for the year ended December 31, 2024. Our independent registered public accounting
firm is not required to formally attest to the effectiveness of our internal control over financial reporting until after we are no longer
an “emerging growth company” as defined in the JOBS Act or a “smaller reporting company” as defined in Item 10(f)(1)
of Regulation S-K. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it
is not satisfied with the level at which our internal control over financial reporting is documented, designed or operating. Any failure
to maintain effective disclosure controls and internal control over financial reporting could have an adverse effect on our business and
results of operations and could cause a decline in the price of the FutureTech Common Stock.

| 57 |

Litigation and other legal
proceedings may adversely affect our business.

From time to
time we may be involved in various litigation matters, which could have an adverse impact on our reputation, brands, and business and
financial condition, and divert the attention of our management from the operation of our business. Claims arising out of actual or alleged
violations of law could be asserted against us by individuals, either individually or through class actions, by governmental entities
in civil or criminal investigations, and by other entities in civil litigation. These claims could be asserted under a variety of laws,
including but not limited to patent, trade secret and other intellectual property claims, product liability claims, employee claims, tort
or contract claims, and federal regulatory investigations. These actions could expose us to adverse publicity and to substantial monetary
damages and legal defense costs, injunctive or other equitable relief, and criminal and civil fines and penalties.

Product liability and other
claims against us may reduce demand for our products or result in substantial damages, and litigation and other legal proceedings may
adversely affect our business.

Our business
exposes us to potential liability for risks that may arise from the clinical testing of our product candidates, the use of our products
by patients or physicians, and the manufacture and sale of any approved products. An individual may bring a product